Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Study Looks At HIV, Risk Behaviors Among Male Clients Of Sex Workers In Tijuana, Mexico
"A large percentage" of U.S. and Mexican men who regularly engage in sexual activity with sex workers in Tijuana, Mexico, do not use condoms and have a history of substance and alcohol use, according to a study published in the online journal AIDS, the Los Angeles Times" blog "L.A. Now" reports. The study, by researchers from Mexico and the University of California-San Diego, surveyed 400 men - both Mexico and U.S. residents - and found that half of the men had unprotected sex with a female sex worker within the last four months. Researchers noted that although Tijuana authorities require that sex workers be registered and tested regularly for HIV, "only about half of [sex workers] have registered or been tested," according to the blog. Thomas Patterson of the UC-San Diego"s department of psychiatry and the Veterans Affairs health center, said the findings indicate a need for an educational campaign targeting men who frequent sex workers (Perry, 7/11).
generic viagra online
If You Have Taken Flomax(R), Tell Your Ophthalmologist BEFORE Having Cataract Surgery
The results of a new study reinforce an advisory that patients taking
News of the day
TAU Develops Tiny Device To "Sniff Out" Disease, Heart Attacks, Poison And Environmental Pollution
Like the sensitive seismographs that can pick up tremors of impending earthquakes long before they strike, a similar invention from Tel Aviv University researchers may change the face of molecular biology.
Oncology

Rolofylline Did Not Demonstrate Efficacy For Acute Heart Failure In Clinical Trial

Merck & Co., Inc. said that preliminary results for the pivotal Phase III study of rolofylline (MK-7418), the Company"s investigational medicine for the treatment of acute heart failure, show that rolofylline did not meet the primary or secondary efficacy endpoints. While Merck will continue to analyze the data with outside experts, the Company will not file applications for regulatory approval this year. The results from this study will be presented at a medical meeting later this year. "Advances to help patients with acute heart failure, a disease that is the leading cause of hospitalization for patients over age 65 and that is associated with a high rate of mortality, have long been elusive," said Dan Bloomfield, M.D., executive director, cardiovascular research, Merck Research Laboratories. "These results are disappointing because we had been hopeful that blocking the adenosine A1 receptor with rolofylline would prove to be a useful new approach for these patients. "Merck remains committed to discovering and developing novel treatments for heart failure and for cardiovascular disease, which claim more than 17 million lives worldwide each year and remain the leading cause of death and a leading cause of disability," Dr. Bloomfield said. The primary hypothesis of the 2,033-patient pivotal Phase III study, PROTECT, was that rolofylline 30 mg would improve symptoms of acute heart failure compared to placebo. The secondary endpoints were that rolofylline 30 mg would reduce the risk of death or cardiovascular or renal re-hospitalization 60 days after treatment, and that rolofylline 30 mg would reduce the incidence of persistent kidney impairment. Details on the design of PROTECT are available at http://www.clinicaltrials.gov, identifiers NCT00328692 and NCT00354458. Rolofylline was acquired by Merck through NovaCardia, which Merck purchased in 2007. Results from the PROTECT pilot study, presented at previous medical meetings and published in 2008, had showed an overall trend toward efficacy (more patients with improved shortness of breath, fewer patients with worsening renal function and/or worsening heart failure). Merck"s late-stage pipeline of investigational medicines for cardiovascular disease includes MK-524A (approved in some markets outside the U.S.), MK-524B, ezetimibe/atorvastatin, and anacetrapib (MK-0859) for atherosclerosis, and vernakalant for atrial fibrillation. Merck


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009